Related by context. All words. (Click for frequent words.) 71 blinded placebo controlled 66 By JENNIFER LEARN 66 single ascending dose 66 INSPIRE Trial Phase III 66 multicentre randomized double 66 number NCT# ClinicalTrials.gov 65 controlled multicenter 65 treatment naïve genotype 65 dose escalation clinical 65 LAB CGRP 64 placebo controlled dose escalation 64 diagnosed Ph + 64 dose escalation trial 64 NOXAFIL Oral Suspension 64 hyperphenylalaninemia HPA due 64 blinded randomized placebo controlled 64 Phase III multicenter 64 XIENCE V Stent System 64 double blinded placebo 63 treatment naive genotype 63 multicenter randomized double 63 non splenectomized 63 TMC# C# 63 multicenter multinational 63 randomized blinded placebo 63 designated HVTN 63 Trial Evaluating 63 randomized multicenter 63 humanized interleukin 6 63 placebo controlled Phase III 63 ACTEMRA TM 63 relapsed MM 63 REVIVE Diabetes 63 Callisto initiated 62 approved incretin mimetic 62 blind multicenter 62 IIa Clinical Trial 62 phase IIb study 62 dyskinesia PD LID 62 PLX STROKE targeting 62 multiple ascending dose 62 myelodysplastic myeloproliferative diseases 62 YOUR LOCAL ANIMAL SHELTER 62 blind placebo controlled 62 dose dose escalation 62 multinational multicenter randomized 62 symptomatic BPH 62 Sapacitabine 62 BCG vaccinated 62 IMiDs ® compound 62 humanized therapeutic 62 ascending dose 62 8mg/kg 61 Multicentre 61 Combination REOLYSIN R 61 intravenous RSD# 61 Phase Ib IIa 61 systemic juvenile idiopathic 61 dose escalation study 61 prasterone 61 Aryplase 61 multicenter prospective 61 Oral Fingolimod 61 randomized placebo controlled 61 weekly subcutaneous injections 61 venlafaxine XR 61 multicenter Phase III 61 CIMZIA R 61 Ribavirin causes 61 brand ciclesonide HFA 61 multicenter Phase II 61 Lymphocytic 61 lenalidomide Revlimid R 61 opioid naive 61 Pharmacokinetics PK 61 primary hypercholesterolemia 61 blind randomized placebo 61 multicentre 61 stage IIIb IV 61 rheumatoid arthritis psoriatic arthritis 61 discontinued Viread 61 evaluating tivozanib 61 virologically suppressed 61 Parkinson disease levodopa induced 61 antiretroviral naive 61 HIV uninfected 61 Engerix B 61 headache nasopharyngitis 61 phase Ib 61 Complicated Skin 61 PET FROM 61 MenACWY 61 HCV SPRINT 61 recurrent glioblastoma multiforme 61 NOX E# 61 receiving CIMZIA #mg 61 purified inactivated vaccine 61 phase III isavuconazole 61 Phase III randomized 61 PRN FDA Approves 61 Study Evaluating 61 intravesical infusion therapy 60 Randomized Controlled 60 placebo controlled Phase 60 CYP#A# CYP#D# 60 novel VDA molecule 60 Study ARIC 60 moderate hepatic impairment 60 placebo controlled 60 Initiated Phase 60 label dose escalation 60 bone marrow reticulin deposition 60 chronic myeloid 60 multicenter placebo controlled 60 masked placebo controlled 60 blind randomized 60 Phase IIIb 60 double blinded randomized 60 Relapsing Multiple Sclerosis 60 basal bolus regimen 60 RhuDex ™ 60 oropharyngeal candidiasis OPC 60 eosinophilic asthma 60 antiretroviral naïve 60 orally administered synthetic retinoid 60 relapsed refractory multiple myeloma 60 Patients Treated With 60 #mg/day [001] 60 Mg Uk 60 Initiate Phase 60 Randomized Double blind 60 autoantibody positive 60 mg q#h 60 VEGFR2 inhibitor 60 kidney urologic 60 Naive Patients 60 decompensated liver disease 60 multicenter randomized 60 Demonstrates Positive 60 AIR CF1 60 infliximab monotherapy 60 Study ADX# 60 aripiprazole Abilify 60 unstable angina UA 60 memantine HCl 60 Long Term Efficacy 60 de novo kidney transplant 60 Phase Ia 60 albiglutide 60 oral dual endothelin 60 AIR2 Trial 60 PRTX 60 aggressive systemic mastocytosis 60 Phase IIIb study 60 myocardial infarction ventricular fibrillation 60 systemic RNAi therapeutic 60 Completes Patient Enrollment 60 Budesonide foam crofelemer 60 HCV NS5B polymerase 60 pralatrexate injection folate analogue 60 Treatment Experienced 60 prospective observational 60 LC#m# vaccine 60 FluCAM arm 60 Non Alcoholic Steatohepatitis 60 II Clinical Trial 59 CHAMPION PCI 59 Crofelemer budesonide foam 59 ascending doses 59 Empatic ™ 59 insulin glulisine 59 Investigational Treatment 59 SNT-MC#/idebenone 59 administered intramuscularly 59 Kit CD# positive 59 multicenter phase 59 pharmacogenomic translational research 59 recombinant PSMA vaccine 59 somatostatin analog 59 dirucotide MBP# 59 Certolizumab pegol 59 phase IIa 59 label multicenter 59 BRIM2 59 Mg Usa 59 Multicenter Study 59 GAMMAGARD 59 Phase 2a trial 59 RoACTEMRA 59 Phase III Clinical Trial 59 VICTOR E1 59 IMiDs ® 59 multicenter randomized placebo controlled 59 Juvenile Idiopathic Arthritis 59 randomized controlled multicenter 59 CRM# Protein 59 mild hepatic impairment 59 Systemic Sclerosis 59 refractory chronic lymphocytic 59 CATIE AD 59 BRIM3 59 atopic asthma 59 selective modulator 59 thrombin inhibiting aptamer 59 topically applied SEPA 59 Clinical Study 59 GetGoal Phase III 59 comparing XIENCE V 59 CTA# Injection 59 multicentre prospective 59 RECORD1 59 mGluR5 NAM 59 recurrent glioma 59 SORT OUT III 59 double blind placebo 59 vapreotide acetate 59 randomized crossover 59 personalized dendritic cell 59 reuptake inhibitor 59 randomized double 59 ABSORB clinical 59 bepotastine besilate nasal spray 59 Controlled Trial 59 LHON 59 TO AVOID PREGNANCY WHILE 59 via intradermal injections 59 HCD# [002] 59 antibody MAb 59 CIMZIA TM certolizumab pegol 59 Telik logo TELINTRA 59 REFORMERS UNANIMOUS Weekly 59 unresectable recurrent 59 Initiates Phase II 59 Carotid Revascularization Endarterectomy vs. 59 TG MV 59 active comparator 59 Prospective Randomized 59 pharmacokinetic PK 59 CYT# potent vascular disrupting 59 relapsing remitting MS RRMS 59 papillary renal cell carcinoma 59 Phase 2b Clinical Trial 59 receiving INTRON 59 malignant mesothelioma Alfacell 59 PREZISTA r 59 acyclovir Lauriad R 59 Presents Positive 59 Adalimumab 59 Refractory Hodgkin Lymphoma 59 Multiple Ascending Dose 59 ritonavir boosted 58 Viread tenofovir disoproxil fumarate 58 naïve HCV 58 dose intramuscular 58 AIR CF2 58 Pooled Analysis 58 PORxin TM platforms 58 reduce serum phosphate 58 recurrent metastatic ovarian cancer 58 RANK Ligand inhibitor 58 either acutely decompensated 58 EQUIP OB 58 Pivotal Phase III 58 Testosterone MDTS R 58 Chronic Heart Failure 58 pharmacokinetics PK 58 Newly Diagnosed Multiple Myeloma 58 complement inhibitor eculizumab 58 DG# compounds targeting 58 placebo controlled clinical 58 LUX Lung 58 progressive PsA 58 chronic eosinophilic leukemia 58 demonstrated antitumor activity 58 Meets Primary Endpoint 58 Phase 1b trial 58 Phase 1b clinical 58 placebo PBO 58 Alzheimer Disease Cooperative 58 prospective randomized multicenter 58 Telithromycin 58 selective phosphodiesterase 58 virus HCV infection 58 Completes Enrollment 58 Multicenter Phase 58 protease inhibitor PI 58 Prostate Lung Colorectal 58 GATTEX ™ 58 Ovitrelle R Serostim 58 Screening Trial 58 Chronic Idiopathic Constipation 58 Receives Marketing Authorization 58 Peginterferon 58 HIV coinfected 58 peripheral neuropathic pain 58 chronic ITP patients 58 metastatic GIST 58 BY WILLA J. 58 advanced metastatic renal 58 evaluating mipomersen 58 psoriatic arthritis PsA 58 combines bupropion 58 placebo controlled randomized 58 Subgroup Analysis 58 interferon gamma 1b 58 EDEMA3 58 LymphoStat B belimumab 58 Randomized Phase 58 MAGE A3 ASCI 58 null responder HCV 58 SPRYCEL ® 58 RELOVAIR ™ 58 dasatinib Sprycel ® 58 GH deficiency 58 MEK Inhibitor 58 Cystic fibrosis affects 58 valsartan amlodipine 58 Sanofi Pasteur Fluzone 58 Cutaneous T 58 Randomized Double Blind 58 Multicenter Randomized Double 58 non nucleoside inhibitor 58 unresectable HCC 58 plus COPEGUS 58 hypereosinophilic syndrome 58 TYGACIL 58 THAT ARE DIFFICULT TO 58 CEL SCI Phase III 58 sunitinib Sutent ® 58 ARIXTRA R 58 Phase IIb Trial 58 recurrent metastatic 58 Alpha Tocopherol Beta Carotene 58 plus prednisone prednisolone 58 systemic Phase 1b 58 Placebo Controlled 58 plus methotrexate 58 forodesine 58 C1 Inhibitor 58 toenail onychomycosis 58 FLUPAN 58 Tanespimycin 58 rALLy clinical trial 58 Pivotal Trial 58 Tocilizumab 58 INVEGA ® 58 dose escalation phase 58 BR.# 58 safety tolerability pharmacokinetics 58 hyperlipidemic 58 registrational Phase 58 signal detection CTSD 58 dose escalation Phase 58 diabetic neuropathic pain 58 pharmacodynamics 58 onset idiopathic hypogonadism 58 HIV HCV coinfected 58 Relapsed Refractory 58 prospective multicentre 58 Raptiva r 58 lintuzumab SGN 58 EchoCRT 58 Systemic Juvenile Idiopathic 58 Randomized Phase II 57 serum phosphorous 57 Charles Dullin School 57 Phase IIIb clinical 57 PD LID 57 ARIXTRA 57 randomized Phase III 57 Bacille Calmette Guérin BCG 57 Phase III Pivotal 57 INTEGRILIN R 57 dopamine receptor agonist 57 erlotinib Tarceva ® 57 genotype 1b 57 HGS ETR1 mapatumumab 57 Phase 1b clinical trials 57 KRAS mutations occur 57 worsening thrombocytopenia 57 pegylated interferon alfa 2a 57 Botswana Lesotho Malawi Mozambique 57 fluticasone furoate 57 See CLINICAL PHARMACOLOGY 57 chronic idiopathic thrombocytopenic purpura 57 AVONEX ® 57 methylnaltrexone bromide 57 Flu Cy 57 Edge STudy 57 Myelodysplastic Syndromes MDS 57 Severe Sepsis 57 heFH 57 Dupuytren Contracture 57 DAPT Study 57 High Dose quadruples 57 Pegasys ® 57 Phase III placebo controlled 57 mitoxantrone plus 57 prednisone prednisolone plus 57 pediatric Crohn disease 57 HBeAg negative 57 evaluating MGCD# [002] 57 mcg kg REBETOL 57 CALGB # [002] 57 undergoing elective percutaneous 57 Proellex TM 57 XL# anticancer compounds 57 Unstable Angina 57 multicentre randomized 57 metastatic neuroendocrine tumors 57 EURIDIS 57 NS5B polymerase 57 FOLOTYN ® 57 golimumab CNTO 57 somnolence dizziness 57 Curis collaborator Genentech 57 PPI omeprazole 57 Amrubicin 57 Phase Ib 57 multicenter randomized controlled 57 Initiates Enrollment 57 atypical Hemolytic Uremic Syndrome 57 EQUATE OB 57 radiolabeled TM# 57 congenital toxoplasmosis 57 Sodium oxybate 57 patients undergoing percutaneous 57 inhalations twice 57 6 sulfatase 57 membranous nephritis 57 maximally tolerated dose 57 limiting generalizability 57 retrospective cohort 57 COMFORT II 57 #rd Annual CTRC 57 CLL8 57 Initiates Phase III 57 administered intranasally 57 genotype 1a 57 Vitrasert R 57 refractory acute myeloid 57 hay fever allergic rhinitis 57 essential thrombocythemia ET 57 DIRECT Trial 57 Poorly Controlled 57 4mg/kg 57 Azacitidine 57 R lenalidomide 57 PKC# 57 multicenter 57 deCODE AF TM 57 IIa clinical 57 Pentacel R 57 IIa trial 57 Randomized Study 57 mg administered orally 57 Phase 2a clinical 57 galiximab 57 AERAS-#/Crucell Ad# 57 prospective randomized placebo 57 metastatic pancreatic 57 Blinatumomab 57 Clinical Trial Evaluating 57 offers deCODE T2 57 Relapsed Multiple Myeloma 57 MKC# MT 57 Cerebral Amyloid Angiopathy 57 Achieves Primary Endpoint 57 oral ghrelin agonist 57 Folfox 57 observational cohort 57 Pruvel TM 57 desvenlafaxine succinate 57 IBS C 57 Tuberculosis Vaccine 57 Is Well Tolerated 57 Phase IIa Clinical Trial 57 azilsartan medoxomil 57 Intervention Effectiveness 57 Chronic Hepatitis C 57 splenectomized 57 Philadelphia Chromosome Positive 57 Adjunctive Therapy 57 Clinical Antipsychotic Trials 57 sodium glucose cotransporter 57 oral antidiabetic medication 57 Omacetaxine mepesuccinate 57 chronic immune thrombocytopenic 57 receptor tyrosine kinase inhibitor 57 Paxil paroxetine 57 Amgen Neulasta ® 57 Hsp# Inhibitor 57 B Anflu R 57 aged ≥ 57 EOquin TM phase 57 icatibant 57 budesonide MMX Phase III 57 Advanced Melanoma 57 phase IIb clinical 57 Demonstrates Sustained 57 SJIA 57 Chronic Hepatitis B 57 q8h 57 ViaDerm hPTH #-# 57 Adjuvant Treatment 57 YONDELIS 57 Ovarian PLCO Cancer 57 landmark ATHENA 57 ZOMIG 57 Vascular Disrupting Agent 57 chronic HCV genotype 57 oral FTY# 57 Demonstrates Potent 57 induced mucositis 57 LHRH receptor positive 57 Bronchiectasis 57 reactogenicity 57 randomized 57 smoldering multiple myeloma 57 thetreatment 57 NO# [002] 57 oral Janus kinase 57 Receives Orphan Drug Designation 57 antidepressants fluoxetine 57 multicenter Phase 57 adult chronic ITP 56 Hypertensive adverse reactions 56 Nonalcoholic fatty liver 56 Focetria 56 ug dose 56 tumors GIST 56 SCIg 56 TTR amyloidosis 56 rheumatoid arthritis osteoarthritis ankylosing 56 alemtuzumab treated 56 prokinetic agent 56 del 5q MDS 56 albiglutide currently 56 Primary endpoints 56 Alferon LDO 56 Initiates Clinical Trial 56 inactivated strain 56 vaccinated PNH patients 56 BARACLUDE ® 56 hemagglutination inhibition HAI 56 HCV Protease Inhibitor 56 sapacitabine CYC# 56 Cardiac Allograft Rejection 56 Vaccine Adjuvant 56 Phase #b/#a trial 56 COU AA 56 LEXIVA r 56 prospectively randomized 56 novel chimeric natriuretic 56 HBeAg positive 56 ongoing Phase 1b 56 retinal vein occlusion induced 56 blind randomized controlled 56 retrospective cohort study 56 ribavirin Copegus 56 Novartis Trileptal 56 Phenoptin 56 Dialysis Outcomes 56 ALN HPN 56 Trodusquemine MSI 56 Ph + acute lymphoblastic 56 iobenguane 56 primary generalized tonic 56 R entecavir 56 underwent CABG 56 randomized multicenter trial 56 APTIVUS r 56 LibiGel Phase III 56 FEMALES SHOULD BE ADVISED 56 seronegative 56 beclomethasone dipropionate 56 glucose intolerant 56 Val HeFT 56 Hepatocellular Carcinoma HCC 56 prospective cohort 56 Forodesine HCl 56 oral rivaroxaban 56 comparing alemtuzumab 56 iloprost synthetic compound 56 Testosterone MDTS ® 56 ATRA IV 56 Researchers randomly assigned 56 phase IIIb 56 CCR5 mAb 56 APTIVUS 56 Phase #/#a 56 IS TO MAKE 56 colesevelam HCl 56 metastatic androgen independent 56 #:#-#,# CrossRef Medline [001] 56 pulmonology portfolio 56 Antitumor Activity 56 metastatic dermatofibrosarcoma protuberans DFSP 56 ovariectomized 56 AFREZZA TM 56 Safinamide 56 5 HT2A inverse 56 Diamyd ® 56 induced macular edema 56 #mg q8h 56 Kinesin Spindle Protein KSP 56 GOUT 56 BEXXAR Therapeutic Regimen 56 schizophrenia schizoaffective disorder 56 ORENCIA ® 56 evaluating carfilzomib 56 cell carcinoma RCC 56 mg kg Hematide 56 undergoing androgen deprivation 56 orally administered inhibitor 56 stable angina pectoris 56 ergot derivatives 56 peripherally acting 56 TransVax ™ 56 CMV seropositive 56 pediatric glioma 56 Pre RELAX AHF 56 ascending dose study 56 refractory anaplastic astrocytoma 56 vinca alkaloid 56 Improves Outcomes 56 evaluating REVLIMID 56 Placebo controlled 56 mRNA antagonist 56 undergone radical prostatectomy 56 Motesanib 56 Pentacel vaccine 56 clinical trials Archexin 56 hematological parameters 56 DEB# 56 intravitreal insert 56 smoldering myeloma 56 imatinib Gleevec ® 56 recurrent malignant glioma 56 T1DM 56 Pneumococcal disease affects 56 Diabetic Macular Edema 56 Therapeutic Efficacy 56 achieved ACR# 56 elevated serum creatinine 56 mcg QD 56 Granted Orphan Drug 56 AVOREN 56 RE SURGE 56 Sustained Efficacy 56 nucleoside naive 56 cerebrovascular disorders 56 CAELYX 56 Randomized Double Blind Placebo 56 randomized controlled 56 RRMS patients 56 neovascular form 56 diphtheria pertussis whooping cough 56 Phase Ib clinical 56 nucleotide analogue 56 Soft Tissue Sarcoma 56 Shows Promising 56 #mg QD [002] 56 APEX PD 56 TELINTRA R 56 Severe Asthma 56 ORACLE MS 56 topically administered 56 sulfonylurea glimepiride 56 5mg/kg 56 Myocardial Infarction Study 56 ovarian endometrial 56 Presents Preclinical 56 multicentre study 56 APPRAISE 56 lexidronam injection 56 Kahalalide F 56 -#.# log# copies mL 56 oxycodone CR 56 adjunctive ABILIFY 56 LEVAQUIN ® 56 unique alkylating agent 56 Betaferon R 56 IFN alfa 56 coinfected patients 56 ritonavir boosted atazanavir 56 immunocompetent 56 alfa 2a 56 virus HCV protease inhibitor 56 Valcyte tablets 56 pitavastatin 56 Ophena TM 56 IIa clinical trial 56 hypercholesterolemic 56 See WARNINGS 56 dyslipidemia hypertension diabetes 56 Heterozygous Familial Hypercholesterolemia 56 Neupro R 56 PEG INTRON R 56 canakinumab 56 abacavir lamivudine 56 Dose Escalation 56 CML CP 56 oral prodrug 56 CINQUIL 56 trivalent inactivated influenza 56 darunavir r 56 Demonstrates Efficacy 56 nondiabetic 56 MULLIGAN FAMILY FUN CENTER 56 Aflibercept 56 relapsed leukemia 56 Initiate Clinical Trial 56 Systemic Lupus Erythematosus SLE 56 BENICAR HCT 56 denileukin diftitox 56 COLAZAL ® 56 HCV RESPOND 2 56 Synta Announces 56 Bosutinib 56 rosuvastatin #mg 56 placebo controlled studies 56 phase IIb trial 56 Eculizumab 56 prospectively evaluated 56 Sorafenib HCC Assessment 56 ginkgo biloba extract 56 EFFEXOR XR 56 cancer indications bafetinib 56 mixed hyperlipidemia 56 Ischemic Stroke 56 ISTODAX ® 56 evaluating Actimmune 56 Humanized Anti 56 Phase 1a clinical 56 microbiologically evaluable 56 Trandolapril 56 Institute DCRI 56 Cancer Incidence Mortality 56 multicenter study 56 ExTRACT TIMI 56 Sangamo BioSciences Announces 56 orally inhaled migraine 56 arsenic trioxide injection 56 GATTEX ® 56 placebo controlled multicenter 56 nilotinib Tasigna ® 56 allosteric modulator NAM 56 Phase IIa trial 56 leukemia AML 56 mGluR5 negative 56 dihydroergotamine 56 CTAP# Capsules 56 adalimumab Humira 56 Phase IIb Clinical Trial 55 STRATEGY FOR AN OPEN 55 mGluR2 positive 55 riociguat 55 multicenter randomized clinical 55 imetelstat GRN#L 55 CELVAPAN H#N# 55 Acute Ischemic Stroke 55 Albuferon TM 55 serum lipid levels 55 Navelbine 55 randomized Phase IIb 55 adjunctive placebo 55 relapsed myeloma 55 saline placebo 55 polymerase inhibitor 55 AAG geldanamycin analog 55 GARDASIL ® 55 Phase 1b 55 Clinical Trial Investigating REOLYSIN 55 Pivotal Phase 55 Androxal TM 55 Phase Ib clinical trials 55 PRECiSE 55 Bayer HealthCare Onyx Pharmaceuticals 55 ORMD 55 diarrhea predominant irritable 55 NICE Recommends 55 specific CCR9 antagonist 55 advanced hepatocellular carcinoma 55 6R BH4 55 Celiac disease affects 55 Lupus Nephritis 55 Oral NKTR 55 herpes zoster shingles 55 5 fluorouracil leucovorin 55 Enzastaurin 55 C1 INH deficiency 55 Aplidin R 55 Chronic Renal Failure 55 Endeavor Resolute DES 55 Cytarabine Liposome Injection 55 candesartan cilexetil 55 blinded randomized 55 generation PNP inhibitor 55 acute humoral rejection 55 phase IIa clinical 55 mcg BID 55 THOUSAND DOLLARS IN 55 multicenter clinical 55 Intravenous immunoglobulin 55 Tarceva TM 55 diabetic peripheral neuropathic pain 55 synthetic progestin 55 Phase III confirmatory 55 visilizumab 55 Begins Dosing 55 CONQUER OB 55 STEALTH C 55 CALGB 55 efavirenz EFV 55 pan histone deacetylase 55 Multicenter Randomized 55 Single Dose 55 IL# PE#QQR 55 Aztreonam lysine 55 Accessed #/#/# [001] 55 Group RTOG 55 Raptiva ® 55 PEGINTRON TM 55 multicenter randomized Phase III 55 Ramelteon 55 ZOLINZA 55 EXPLORE Xa 55 cutaneous T 55 Tumor Response 55 metformin HCl 55 Chronic Myelogenous Leukemia CML 55 dosing cohort 55 Intervention Trial 55 NIASPAN 55 Phase Ib II 55 teriflunomide 55 randomized #:# 55 mg Pycnogenol 55 #mg dosing 55 Temsirolimus 55 Phase 2b Study 55 beta carotene supplementation 55 IMPACT DCM trial 55 Transdermal Patch 55 Treatment Naïve 55 hepatitis C HCV 55 Elotuzumab 55 trial evaluating PRX# 55 sorafenib tablets 55 HeFH 55 Protease Inhibitor 55 Pivotal Study 55 protease inhibitors PIs 55 huC# DM4 55 Desvenlafaxine Succinate 55 RhuDex R 55 HQK 55 REG2 55 Crohn disease CD 55 asthma rheumatoid arthritis 55 Ozarelix 55 gastro intestinal inflammation 55 prospective nonrandomized 55 methylphenidate Ritalin 55 Neulasta R 55 Phe restricted diet 55 CC genotype 55 Tasigna prolongs 55 relapsed acute lymphoblastic 55 nadroparin 55 longitudinal cohort study 55 Clinical Evaluation 55 pegylated interferon alpha 55 ceftazidime 55 Teriflunomide 55 Phase IIb clinical 55 receiving VELCADE 55 evaluating T DM1 55 pioglitazone HCl 55 REGN# 55 onset diabetes mellitus 55 includes TOLAMBA TM 55 administered concomitantly 55 underwent liver transplantation 55 CERVARIX 55 TRANSDUR ® 55 OPT CHF 55 thrombocytopenic 55 Phase #b/#a clinical 55 Chronic HCV 55 unfractionated heparin UFH 55 placebo intravenously 55 dependent kinase inhibitor 55 leukopenia pancytopenia thrombocytopenia 55 Diamyd r 55 highly selective inhibitor 55 gastrointestinal stromal 55 FOLFOX6 chemotherapy regimen 55 miconazole Lauriad ® 55 Left Ventricular Dysfunction 55 intravenous bolus 55 ADVANCE PD 55 investigational oral 55 plus Copegus R 55 macrolide antibiotic 55 Multicenter 55 = Array poll uid 55 Aad Schalke Dutch 55 gastrin analogue TT 55 Recurrent Glioblastoma 55 μg dose 55 Successfully Treated 55 R rilonacept Injection 55 budesonide foam 55 melphalan prednisone 55 Phase III Trial 55 TNF antagonist therapy 55 PREZISTA ritonavir 55 Metastatic Melanoma 55 Sudhir Agrawal D.Phil 55 ViRexx licensing 55 taxane resistant 55 diarrhea vomiting nausea 55 Myelodysplastic Syndrome MDS 55 risperidone Risperdal 55 syngeneic 55 Attention-Deficit/Hyperactivity Disorder ADHD 55 Pafuramidine 55 CIMZIA TM 55 Novel Oral 55 refractory CLL 55 Submits NDA 55 dermatologic reactions 55 #mg BID [001] 55 mg/m2 administered 55 Submits Biologics License Application 55 glulisine 55 post herpetic neuralgia PHN 55 pharmacodynamic PD 55 Omacetaxine 55 metastatic castrate resistant 55 genital human papillomavirus 55 Xeloda ® 55 aplastic anemia AA 55 serotonin norepinephrine reuptake inhibitor 55 pharmacokinetic parameters 55 CYT# QbG# 55 prospective multicenter 55 SSRI citalopram 55 pioglitazone hydrochloride 55 Ib clinical trials 55 Alzhemed TM 55 Therapy Evaluation 55 familial amyloidotic polyneuropathy FAP 55 immunocompetent adults 55 Mylan Receives Approval 55 elevated triglyceride levels 55 minimally symptomatic 55 Successfully Treats 55 Luveris R Ovidrel R 55 R# #mg BID 55 experimental autoimmune encephalomyelitis 55 REGARDS 55 HCV infected 55 hereditary medullary thyroid 55 vaccine LAIV 55 liver transplant recipients 55 constipation OIC 55 mertansine 55 catheter occlusion 55 Triapine 55 Investigational Compound 55 mcg linaclotide 55 Physical Therapy PTJ 55 BiTE R 55 Epothilone D 55 Blind Placebo Controlled 55 Filoli Offers variety 55 R#/MEM # 55 bleeding pallor 55 ZYBRESTAT fosbretabulin 55 Luvox fluvoxamine 55 normotensive 55 Inhalation Solution 55 TKB# 55 Controlled Study 55 IMiDs R 55 Pull Ups diapers 55 eszopiclone 55 Heart Failure Trial 55 comparator arm 55 Receives Positive Opinion 55 Tezampanel 55 stage IIIB 55 Phase 2a Trial 55 intranasally administered 55 patientswith 55 pyridostigmine